Search the Newsreel

AZZ (NYSE:AZZ) COO Sells $401,737.39 in Stock

AZZ COO Bryan Lee Stovall sold 2,677 shares of the company's stock for a total of $401,737.39, reducing his direct ownership by 7.11%. The company recently reported strong quarterly earnings, beating analyst estimates, and increased its quarterly dividend. Analysts maintain a "Moderate Buy" rating …

AZZA3 - Azzas 2154 - Resultados, Dividendos, Cotação e Indicadores

T. Rowe Price (AZZ) cuts AZZ Inc stake to 4.6% of common stock

T. Rowe Price Investment Management, Inc. has filed an amended Schedule 13G, reporting a reduced beneficial ownership in AZZ Inc. to 4.6% of its common stock. The firm now holds 1,385,963 shares, granting it sole voting and dispositive power over these shares, and has …

Irish Jazz Pharmaceuticals acquires American Actio for $1.32 billion

Irish biopharmaceutical company Jazz Pharmaceuticals plc has announced its acquisition of American Actio Biosciences, Inc. for $1.32 billion. The deal involves an upfront payment of $820 million and an additional $500 million contingent on drug approval and sales milestones. Jazz will gain control of …

Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. significantly reduced its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 96.7% in the second quarter, selling 309,427 shares and retaining 10,573 shares valued at $2.55 million. Despite this, institutional investors and hedge funds collectively own 89.14% of the company, and …

Azzas 2154 (AZZA3) ainda não convence: 2T26 mais fraco mantém mercado à espera de sinais de recuperação

AZZ President & COO of the Precoat Metals Business Segment Jeffrey Vellines Sells 70% Of Holding

Jeffrey Vellines, President & COO of AZZ's Precoat Metals Business Segment, recently sold US$648k worth of stock, representing 70% of his holding. This sale follows a larger transaction by President Thomas Ferguson earlier, raising questions about insider confidence. While insiders hold 1.9% of AZZ …

Jazz Pharmaceuticals (JAZZ) Stock Looks Cheap On Earnings While Broader Checks Stay Mixed

Jazz Pharmaceuticals (JAZZ) stock has shown a significant return of 112.6% over the past year. Despite this performance and recent deal activity, the stock appears undervalued based on its P/E ratio of 17.2x, which is on par with the industry average but significantly lower …

Azz Pres & COO Jeffrey Vellines sells $647,981 of company stock

Jeffrey Vellines, President and COO of Precoat Metals at AZZ INC, sold 4,220 shares of company stock for a total of $647,981 on August 11, 2026. The shares were sold at an average price of $153.55. This insider sale comes as AZZ shares trade …

Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout (JAZZ)

Wedge Capital Management L L P NC Sells 33,467 Shares of Jazz Pharmaceuticals PLC $JAZZ

Wedge Capital Management L L P NC reduced its stake in Jazz Pharmaceuticals PLC by 20.9% in the second quarter, selling 33,467 shares and retaining 126,539 shares valued at approximately $30.5 million. Despite missing quarterly EPS estimates, the company's revenue exceeded expectations, and analysts …

Jazz Pharmaceuticals (JAZZ) Q2 2026 Earnings Call Transcript

Jeffrey Vellines Sells 4,220 Shares of AZZ (NYSE:AZZ) Stock

Jeffrey Vellines, COO of AZZ Inc. (NYSE:AZZ), sold 4,220 shares of the company's stock on August 11, 2026, for a total of $647,981, reducing his direct ownership by 69.71%. The sale occurred as AZZ shares traded near their 52-week high, following a quarter where …

AZZ Inc. (AZZ) lists common stock and equity awards for potential resale

AZZ Inc. has filed a Form 144 indicating a potential resale of its common stock and equity awards through Morgan Stanley Smith Barney LLC. The filing details 4,220 common shares valued at $647,982.27, along with restricted stock and performance shares from April 2026. This …

Royal Bank of Canada Has $8.56 Million Stake in Jazz Pharmaceuticals PLC $JAZZ

Royal Bank of Canada increased its stake in Jazz Pharmaceuticals PLC by 17.4% in the first quarter, now holding 45,251 shares valued at $8.56 million. Institutional investors collectively own 89.14% of JAZZ shares, reflecting positive sentiment despite a recent EPS miss. Jazz Pharmaceuticals reported …

Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal

Jazz Pharmaceuticals has agreed to acquire Actio Biosciences, a private biotech specializing in genetic epilepsy treatments, for an upfront payment of $820 million and potential milestone payments of $500 million, totaling $1.3 billion. The acquisition will bolster Jazz's neuroscience pipeline, particularly with Actio's lead …

Jazz Pharmaceuticals to Acquire Rare Epilepsy Specialist Actio

Jazz Pharmaceuticals (JAZZ) announced its acquisition of Actio Biosciences for $820 million upfront and up to $500 million in milestone payments, expected to close by late 2026. This strategic move strengthens Jazz's rare epilepsy portfolio with the addition of ABS-1230, a promising therapy for …

Jazz Pharmaceuticals to acquire Actio Biosciences for $820M

Jazz Pharmaceuticals announced its acquisition of Actio Biosciences for an upfront payment of $820 million, with potential additional payments of up to $500 million tied to milestones. The acquisition is primarily focused on ABS-1230, a clinical-stage drug for KCNT1+ epilepsy, a rare genetic disorder …

Oliver Luxxe Assets LLC Reduces Holdings in AZZ Inc. $AZZ

Oliver Luxxe Assets LLC significantly reduced its stake in AZZ Inc. by 46.5% in the second quarter, selling over 8,400 shares and retaining a position valued at approximately $1.5 million. Despite this reduction by one firm, institutional investors collectively own a substantial 90.93% of …

5 Revealing Analyst Questions From Jazz Pharmaceuticals’s Q2 Earnings Call

5 Revealing Analyst Questions From Jazz Pharmaceuticals's Q2 Earnings Call Jazz Pharmaceuticals delivered a positive Q2, with a strong 16% year-over-year revenue increase driven primarily by its oncology and rare disease portfolios. Management attributed the quarter's performance to robust demand for flagship products like …

Jazz Pharmaceuticals plc (JAZZ) stock price, news, quote and history

This article provides a detailed overview of Jazz Pharmaceuticals plc (JAZZ), including its stock price, news, and historical data. It covers the company's financial performance, product pipeline, analyst ratings, and compares it with similar biotechnology companies. The information presented aims to give investors a …

Jazz Pharmaceuticals PLC (JAZZ) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Jazz Pharmaceuticals PLC (JAZZ), highlighting its current earnings forecast score, average price target, and analyst ratings. It details expected future EPS and revenue growth, along with recent performance and a peer comparison. The forecast indicates a "Buy" …

Jazz Pharmaceuticals plc 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:JAZZ) 2026-08-07

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) published its Q2 2026 earnings call presentation, detailing its financial results. The company reported an EPS of $5.71, missing estimates by $0.47, but revenue reached $1.21 billion, surpassing expectations by $93.90 million with a 15.55% year-over-year increase. This presentation provides …

Jazz Pharmaceuticals plc SEC Filing (Aug 7, 2026)

Jazz Pharmaceuticals plc has filed a Form 144 SEC filing on August 7, 2026, concerning a proposed sale of securities. The filing indicates a neutral impact and sentiment according to AI-generated analysis by StockTitan. It details information about the issuer, the filer (Etrade Financial …

Jazz Pharmaceuticals plc (JAZZ) News, Articles, Events & Latest Updates

Jazz Pharmaceuticals (JAZZ) reported strong Q2 2026 results, exceeding sales estimates and raising its 2026 revenue guidance, despite an EPS miss. The company's performance was driven by robust demand in its oncology and neuroscience segments, leading to a stock jump and mixed analyst reactions, …

AZZ beats Q1 estimates, raises full-year guidance; Shares jump 7%

AZZ Inc. (NYSE:AZZ) surpassed first-quarter analyst expectations for both adjusted EPS and revenue, leading to a 6.5% jump in shares. The company also raised its full-year fiscal 2027 guidance for both adjusted EPS and revenue, citing strong sales momentum in its Metal Coatings and …

Jazz Pharmaceuticals Plc Just Missed EPS By 13%: Here's What Analysts Think Will Happen Next

Jazz Pharmaceuticals Plc recently reported its quarterly earnings, missing analyst EPS estimates by 13%. This article discusses the company's latest financial results and provides an overview of how analysts are adjusting their future earnings and revenue forecasts in light of this performance. It highlights …

FMR LLC and Abigail Johnson disclose 7.4% Jazz Pharmaceuticals (JAZZ) ownership

FMR LLC and Abigail P. Johnson have reported beneficial ownership of 7.4% of Jazz Pharmaceuticals plc common stock, according to a SCHEDULE 13G SEC filing. FMR LLC holds 4,675,458.82 shares, with sole voting power over 4,618,210.03 shares and sole dispositive power over all its …

FMR LLC (AZZ) discloses 1.45M-share, 4.8% beneficial stake in AZZ INC

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 1,450,299.30 shares, or 4.8%, of AZZ INC common stock as of June 30, 2026, through a Schedule 13G/A filing. FMR LLC holds sole dispositive power over these shares and sole voting power …

Jazz Pharmaceuticals (JAZZ) Director Bruce Cozadd Sells 6,000 Sh

Jazz Pharmaceuticals Director Bruce Cozadd sold 6,000 shares of JAZZ for approximately $1.52 million, bringing his total sales over the past year to 143,000 shares with no purchases. This insider selling activity, combined with the stock trading significantly above its GF Value (price-to-GF-Value ratio …

AZZ Inc. $AZZ Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. reduced its stake in AZZ Inc. by 7.8% in the first quarter, selling 11,657 shares but still retaining 137,968 shares valued at $17.3 million. Despite this, institutional investors collectively own 90.93% of AZZ. The company recently exceeded earnings and revenue expectations, …

Jazz Pharmaceuticals (JAZZ) Stock May Stay Below Fair Value Following Raised Guidance

Jazz Pharmaceuticals' stock has seen a significant surge over the past year, returning 146.9%. Despite this, the company's valuation metrics, particularly its P/E ratio of 18.0x, suggest it might still be undervalued compared to a tailored reference multiple of 24.7x, even after record Q2 …

Janus Henderson Group PLC Increases Stake in AZZ Inc. $AZZ

Janus Henderson Group PLC significantly increased its stake in AZZ Inc. (NYSE:AZZ) by 162.1% in the first quarter, now holding 88,273 shares valued at approximately $11.05 million. This increase contributes to institutional investors collectively owning 90.93% of AZZ. The company reported strong financial results, …